Business
Apellis Highlights Commercial Execution and Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference
Full-year 2025 preliminary1 U.S. net product revenues of $689 millionSYFOVRE® (pegcetacoplan injection) total injection demand grew 17% year-over-year;
About this update from Apellis Pharmaceuticals, Inc.
[{"type":"text","content":"Full-year 2025 preliminary1 U.S. net product revenues of $689 millionSYFOVRE® (pegcetacoplan injection) total injection demand grew 17% year-over-year; regulatory submission for prefilled syringe planned in 1H 2026Strong EMPAVELI® (pegcetacoplan) launch in C3G and primary IC-MPGN continues, with 267 new patient start forms in 2025; more than 5% market penetration following the first full quarter post-launchPivotal trials initiated for EMPAVELI in two additional nephrology indications, FSGS and DGFPreliminary year-end cash and cash equivalents of approximately $466 million; projected revenues, cash and cash equivalents expected to be sufficient to fund operations to profitability WALTHAM, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), today announced preliminary U.S. net product revenues for the fourth quarter and the full year 2025, as well as its strategic priorities for continued growth across the business. “In 2025, we made significant strides across our business, translating focused execution into meaningful commercial and pipeline progress that positions us for strong momentum as we enter 2026,” said Cedric Francois, M.D., Ph.D., chief executive officer at Apellis. “As we look ahead, our priority is expanding the geographic atrophy market and advancing targeted initiatives to further strengthen SYFOVRE’s competitive position and long-term growth potential. EMPAVELI continues to build toward blockbuster status, with more than 5% market penetration in C3G and primary IC-MPGN following its first full quarter post-launch. With a strong balance sheet and growing commercial revenue base, we believe that we are well positioned to self-fund our pipeline and drive long-term sustainable value creation through disciplined financial execution.” Transforming the treatment of geographic atrophy (GA) with SYFOVRE Strong patient demand for SYFOVRE continued with 17% growth in total injections year-over-year.In the fourth quarter of 2025: SYFOVRE remained the clear market leader in GA with total market share of approximately 60%.Consistent total injections quarter-over-quarter reflecting year-end seasonality.Delivered approximately 102K SYFOVRE doses to physician offices, including approximately 89K commercial doses and approximately 13K free goods doses. Recently announced new five-year data from a p...